Editorial Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.33696/cancerbiology.1.002
Angioimmunoblastic T cell Lymphoma Microenvironment
Sergiu Pasca1, Ancuta Jurj2,*, Daniela Matei3,4
- 1Department of Hematology, Iuliu Hatieganu University of Medicine & Pharmacy, 21 December Boulevard, 400124, Cluj-Napoca, Romania
- 2Research Center for Functional Genomics, Biomedicine & Translational Medicine, Iuliu Hatieganu University of Medicine & Pharmacy, 23 Marinescu Street, 400337, Cluj-Napoca, Romania
- 3Department of Gastroenterology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
- 4Octavian Fodor Regional Institute of Gastroenterology-Hepatology, Cluj-Napoca, Romania
Corresponding Author
Ancuta Jurj, ancajurj15@gmail.com
Received Date: April 22, 2020
Accepted Date: April 23, 2020
Pasca S, Jurj A, Matei D. Angioimmunoblastic T cell Lymphoma Microenvironment. Arch Cancer Biol Ther. 2020; 1(1): 11-13
Copyright: © 2020 Pasca S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Angioimmunoblastic T cell Lymphoma Microenvironment
Angioimmunoblastic T cell lymphoma (AITL) is one of the most common T-cell lymphomas, second only to peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). Initially AITL was considered a non-malignant lymphadenopathy with immune hyperactivation, nowadays being classified as a PTCL.
Commentary on “Epigenetically Altered T Cells Contribute to Lupus Flares”
The recently published manuscript entitled “Epigenetically Altered T Cells Contribute to Lupus Flares” summarizes recent advances in our understanding of how the environment alters the immune system to cause flares of systemic lupus erythematosus (SLE) in genetically predisposed people, and why it affects women approximately 9 times more often than men
CAR-T cell Goes on a Mathematical Model
CAR-T cell immunotherapy is a great advance in hematological cancers treatment. New CARs and therapy schemes are being developed and a mathematical model could contribute to a rational design of treatment. Here we comment and show new results with previously published models of CAR-T cell therapy, emphasizing the contribution of initial tumor load, the proliferation of CAR-T cell and inhibition of CAR-T cell activity by the tumor resulting in different scenarios as tumor escape, equilibrium (stable disease) and tumor elimination.
Small-molecule Interferon Inducers for Cancer Immunotherapy Targeting Non-T cell-inflamed Tumors
Since the discovery of escaping mechanism of tumor from negative immune regulation, the paradigm of drug discovery for anti-cancer agents has been dramatically shifted to cancer immunotherapy (e.g., dendritic cell therapy, CAR-T cell therapy, or antibody therapy) by stimulating patient’s immune system to treat cancer.
Humanized Chimeric Antigen Receptor (CAR) T cells
In 1989, researchers proposed an intricate strategy in the field of adoptive cell therapy (ACT). Using the T-cell receptor (TCR) as a template, they replaced the coding sequence for the Vα and Vβ chains with the antigen- recognition domains from an antibody (VH and VL chains).